Chinese expert consensus on Bruton tyrosine kinase inhibitors in the treatment of B-cell malignancies.

MLA

Song, Yuqin, et al. “Chinese Expert Consensus on Bruton Tyrosine Kinase Inhibitors in the Treatment of B-Cell Malignancies.” Experimental Hematology & Oncology, vol. 12, no. 1, Oct. 2023, pp. 1–26. EBSCOhost, https://doi.org/10.1186/s40164-023-00448-5.

APA

Song, Y., Wu, S.-J., Shen, Z., Zhao, D., Chan, T. S. Y., Huang, H., Qiu, L., Li, J., Tan, T., Zhu, J., Song, Y., Huang, W.-H., Zhao, W., Liu, H. S. Y., Xu, W., Chen, N., Ma, J., Chang, C.-S., & Tse, E. W. C. (2023). Chinese expert consensus on Bruton tyrosine kinase inhibitors in the treatment of B-cell malignancies. Experimental Hematology & Oncology, 12(1), 1–26. https://doi.org/10.1186/s40164-023-00448-5

Chicago

Song, Yuqin, Shang-Ju Wu, Zhixiang Shen, Donglu Zhao, Thomas Sau Yan Chan, Huiqiang Huang, Lugui Qiu, et al. 2023. “Chinese Expert Consensus on Bruton Tyrosine Kinase Inhibitors in the Treatment of B-Cell Malignancies.” Experimental Hematology & Oncology 12 (1): 1–26. doi:10.1186/s40164-023-00448-5.